Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-21-036818
Filing Date
2021-06-01
Accepted
2021-06-01 16:19:41
Documents
1
Period of Report
2021-05-28

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1583
  Complete submission text file 0001209191-21-036818.txt   2997
Mailing Address 21823 30TH DR SE BOTHELL WA 98021
Business Address
SIEGALL CLAY B (Reporting) CIK: 0001167496 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39398 | Film No.: 21985560

Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Issuer) CIK: 0001549595 (see all company filings)

EIN.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
SIC: 2834 Pharmaceutical Preparations